CEACAM-8

CEACAM-8

CEACAM-8 Informations sur la molécule

Molecule Name
Non specific cross-reacting antigen 95
Alias de la molécule
CEACAM8,CD66b,CD67,CGM6,NCA-95
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
Contexte de la molécule
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
90Y-DTPA-besilesomabTLX-66Phase 2 ClinicalTelix Pharmaceuticals Ltd
Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Besilesomab99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183ApprovedCis Bio International SaScintimunEUOsteomyelitisCis Bio International Sa2010-01-11
Osteomyelitis
Details